Bioorganic & Medicinal Chemistry Letters 2007-01-01

Ponapensin, a cyclopenta[bc]benzopyran with potent NF-kappaB inhibitory activity from Aglaia ponapensis.

Angela A Salim, Alison D Pawlus, Hee-Byung Chai, Norman R Farnsworth, A Douglas Kinghorn, Esperanza J Carcache-Blanco

Index: Bioorg. Med. Chem. Lett. 17(1) , 109-12, (2007)

Full Text: HTML

Abstract

Two new compounds, a cyclopenta[bc]benzopyran, ponapensin (1), and an aglaialactone, 5,6-desmethylenedioxy-5-methoxy-aglalactone (2), together with nine known compounds were isolated from the CHCl(3) soluble extract of the leaves and twigs of Aglaia ponapensis. Their structures were established by spectroscopic data interpretation. Ponapensin (1) exhibited significant NF-kappaB inhibitory activity in an Elisa assay, and was found to be more potent than the positive control rocaglamide. All of the compounds isolated were also tested in a panel of human cancer cell lines, with the known sterol E-volkendousin (3) and methyl rocaglate (aglafoline) found to be the only active substances.


Related Compounds

Related Articles:

Inhibitors of Translation Targeting Eukaryotic Translation Initiation Factor 4A-Chapter Twenty

2012-01-01

[Meth. Enzymol. 511 , 437-61, (2012)]

Rocaglamide sensitizes leukemic T cells to activation-induced cell death by differential regulation of CD95L and c-FLIP expression.

2009-09-01

[Cell Death Differ. 16(9) , 1289-99, (2009)]

Cyclorocaglamide, the first bridged cyclopentatetrahydrobenzofuran, and a related "open chain" rocaglamide derivative from Aglaia oligophylla.

2003-01-01

[J. Nat. Prod. 66(1) , 80-5, (2003)]

Insecticidal rocaglamide derivatives from Aglaia spectabilis (Meliaceae).

2000-08-01

[Phytochemistry 54(8) , 731-6, (2000)]

Rocaglamide and a XIAP inhibitor cooperatively sensitize TRAIL-mediated apoptosis in Hodgkin's lymphomas.

2012-08-15

[Int. J. Cancer 131(4) , 1003-8, (2012)]

More Articles...